Flexion’s Pandemic Rebound: How Zilretta Dropped 80% But Is Still Coming Out Ahead
Executive Summary
The knee osteoarthritis injection was hit hard by COVID-19 restrictions, at first. But CEO Mike Clayman reflected in an interview about how the pandemic experience is helping fuel further growth for Zilretta.
You may also be interested in...
Oligonucleotides, Oxycodone And Osteoarthritis Among 49 US FDA Guidances
The FDA has seemingly followed the lead of the EMA by guiding ANDA sponsors on how to develop oligonucleotide drugs, a complex class of DNA or RNA molecules.
Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
Bone Has Tough Path Forward After Phase III Knee Osteoarthritis Fail
The company said the study of JTA-004 failed to meet its primary and key secondary endpoints, though a post-hoc analysis indicated activity in a patient subset.